Medprin Regenerative Medical Technologies Co., Ltd. is a China-based medical device and regenerative medicine company engaged in the research, development, manufacturing, and commercialization of high-performance implantable biomaterials, surgical devices, and customized tissue repair solutions. Founded in 2008 and headquartered in Guangzhou, China, the company leverages precision biomaterial forming and biological 3D printing technologies to produce specialized medical products primarily focused on neurosurgery, craniomaxillofacial repair, wound management, and general surgery.
The company operates through three primary business segments: Neurosurgical Implants and Biomaterials, Surgical Equipment and Consumables, and Advanced Wound Care and Regenerative Repair. Its core product portfolio comprises absorbable artificial dural repair patches marketed under the ReDura and NeoDura brand names for cerebral and spinal dural defect repair; patient-specific craniomaxillofacial bone repair systems, including three-dimensional printed polyetheretherketone (PEEK) cranial plates, customized bone meshes, and titanium fixation systems; bioabsorbable surgical hemostatic agents and flowable hemostatic matrices designed for intraoperative bleeding control; neurosurgical surgical power systems, including high-speed electric and pneumatic cranial drills, burs, and precision milling consumables; bioceramic bone graft substitutes and synthetic calcium phosphate bone repair matrices for orthopedic and cranial defect reconstruction; bioresorbable dural sealants and tissue adhesives for fluid-tight surgical closure; and medical-grade custom 3D anatomical modeling and digital surgical planning services. Medprin distributes its products domestically to tertiary hospitals across mainland China and exports internationally to healthcare institutions across Europe, Latin America, Southeast Asia, and the Middle East.
In recent developments, Medprin Regenerative Medical Technologies has accelerated its product portfolio diversification and international commercial expansion. The company has secured expanded regulatory approvals, including National Medical Products Administration (NMPA) Class III registrations and international CE certifications, for its next-generation flowable absorbable hemostatic matrices and customized PEEK bone repair implants. Operationally, the company has expanded its manufacturing and R&D infrastructure in Guangzhou, enhancing automated production lines for biological 3D printing and electrospun nanofiber biomaterials to satisfy growing global clinical demand. Additionally, Medprin has scaled the commercial rollout of its proprietary neurosurgical power tool systems across hospital networks, deepened strategic distribution partnerships throughout Europe and the Asia-Pacific region, and broadened clinical research collaborations focused on regenerative biomaterials for spinal and soft-tissue reconstruction.